Cai Guo

Cai Guo has a diverse work experience in the field of biosciences and research. Their most recent role was as a Principal Scientist - CMC Upstream Development at RemeGen Biosciences, where they provided CMC regulatory strategies and guidance for comparability studies. Prior to that, they worked at Amgen as a Senior Scientist and Scientist in various roles, leading a team and producing therapeutic antibodies. They also conducted cell line development and utilized CRISPR editing tools. Cai Guo started their career as a Postdoctoral Fellow at the California Institute of Technology and City of Hope.

Cai Guo earned a PhD in Biology from the Irell & Manella Graduate School of Biological Sciences from 2003 to 2009. Prior to that, from 1999 to 2003, Cai Guo completed a BS in Biology at Nanjing University.